Anti-IL-6 monoclonal antibodies

Details Anti-IL-6 monoclonal antibodies Anti-IL-6 monoclonal antibodies

2011-04-05

2011-04-05

Mertz, Prema (Department: 1646)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Monoclonal antibody or fragment thereof

C424S141100, C530S388100, C530S388230

Reexamination Certificate

active

07919095

ABSTRACT:
The present invention provides novel monoclonal antibodies that bind specifically to IL-6. The antibodies of the invention comprise a variable heavy chain (VH) region selected from any of the VH regions disclosed herein as well as amino acid variants thereof, and/or a variable light chain (VL) region selected from any of the VL regions disclosed herein as well as amino acid variants thereof. The invention also provides methods of treating diseases and disorders associated with IL-6 expression and/or activity.

REFERENCES:
patent: 5618700 (1997-04-01), Novick et al.
patent: 5693780 (1997-12-01), Newman et al.
patent: 5856135 (1999-01-01), Tsuchiya et al.
patent: 5888510 (1999-03-01), Kishimoto et al.
patent: 6083501 (2000-07-01), Miyata et al.
patent: 6086874 (2000-07-01), Yoshida et al.
patent: 6121423 (2000-09-01), Tsuchiya et al.
patent: 6248516 (2001-06-01), Winter et al.
patent: 6632927 (2003-10-01), Adair et al.
patent: 2002/0051787 (2002-05-01), Prince et al.
patent: 2002/0123057 (2002-09-01), Zauderer et al.
patent: 2002/0168360 (2002-11-01), Dingivan et al.
patent: 2003/0044406 (2003-03-01), Dingivan et al.
patent: 2004/0028681 (2004-02-01), Ito et al.
patent: 2004/0161426 (2004-08-01), Trikha et al.
patent: 2005/0032175 (2005-02-01), Stahl et al.
patent: 2005/0100550 (2005-05-01), Trikha et al.
patent: 2005/0180974 (2005-08-01), Shafer
patent: 2005/0196755 (2005-09-01), Zauderer et al.
patent: 2006/0134113 (2006-06-01), Mihara
patent: 2006/0165696 (2006-07-01), Okano et al.
patent: 2006/0228416 (2006-10-01), Faure et al.
patent: 2006/0257401 (2006-11-01), Stassi et al.
patent: 2006/0257407 (2006-11-01), Chen et al.
patent: 2006/0275294 (2006-12-01), Omoigui
patent: 2006/0292147 (2006-12-01), Yoshizaki et al.
patent: 2007/0009527 (2007-01-01), Muyldermans
patent: 2007/0060521 (2007-03-01), Jove et al.
patent: 39 39 706 (1991-03-01), None
patent: 0 312 996 (1989-04-01), None
patent: 0 410 813 (1989-07-01), None
patent: 0 399 429 (1990-11-01), None
patent: 0 783 893 (1997-07-01), None
patent: 0 800 829 (1997-10-01), None
patent: 1 536 012 (2005-06-01), None
patent: 1 712 241 (2006-10-01), None
patent: WO 98/36061 (1998-08-01), None
patent: WO 98/42377 (1998-10-01), None
patent: WO 99/47170 (1999-09-01), None
patent: WO 99/64070 (1999-12-01), None
patent: WO 00/10607 (2000-03-01), None
patent: WO 01/62287 (2001-08-01), None
patent: WO 02/34292 (2002-05-01), None
patent: WO 02/080969 (2002-10-01), None
patent: WO 2004/020633 (2004-03-01), None
patent: WO 2004/039826 (2004-05-01), None
patent: WO 2004/045507 (2004-06-01), None
patent: WO 2004/073741 (2004-09-01), None
patent: WO 2004/096273 (2004-11-01), None
patent: WO 2005/023193 (2005-03-01), None
patent: WO 2005/080429 (2005-09-01), None
patent: WO 2006/066088 (2006-06-01), None
patent: WO 2006/119767 (2006-11-01), None
Panka et al. Proc. Natl. Acad. Sci. USA vol. 85, pp. 3080-3084 (May 1988).
Rudikoff et al. Proc. Natl. Acad. Sci. USA vol. 79, pp. 1979-1983 (Mar. 1982).
Amit et al. Science, Vot. 233, pp. 747-753, (Aug. 1986).
Mikayama et al. Proc. Natl. Acad. Sci. USA (1993), vol. 90, pp. 10056-10060.
Voet et al. Biochemistry John Wiley & Sons, Inc., (199), pp. 126-128 and 228-234.
Bataille, R., et al., “Biologic Effects of Anti-Interleukin-6 Murine Monoclonal Antibody in Advanced Multiple Myeloma,”Blood86:685-691, The American Society of Hematology (1995).
Bender, P.K., and Larson, T.J., “Chap. 24. PC/GENE: Database Searches,” inMethods in Molecular Biology, vol. 24:Computer Analysis of Sequence Data, Part I, Griffin, A.M., and Griffin, H.G., eds., Humana Press Inc., Totowa, NJ, pp. 289-306 (1994).
Blay, J.-Y., et al., “Role of Interleukin-6 in the Paraneoplastic Inflammatory Syndrome Associated with Renal-Cell Carcinoma,”Int. J. Cancer72:424-430, Wiley-Liss, Inc. (1997).
Brakenhoff, J.P.J., et al., “Structure-Function Analysis of Human IL-6. Epitope Mapping of Neutralizing Monoclonal Antibodies with Amino- and Carboxyl-Terminal Deletion Mutants,”J. Immunol. 145:561-568, The American Association of Immunologists (1990).
Cahlin, C., et al., “Experimental Cancer Cachexia: The Role of Host-derived Cytokines Interlukin (IL)-6, IL-12, Interferon-γ, Tumor Necrosis Factor α Evaluated in Gene Knockout, Tumor-bearing Mice on C57 B1 Background and Eicosanoid-dependent Cachexia,”Cancer Res. 60:5488-5493, American Association for Cancer Research, Inc. (2000).
Campbell, I.L., et al., “Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6,”Proc. Natl. Acad. Sci. USA90:10061-10065, National Academy of Sciences (1993).
Carrillo, H., and Lipman, D., “The Multiple Sequence Alignment Problem in Biology,”SIAM J. Appl. Math. 48:1073-1082, Society for Industrial and Applied Mathematics (1988).
Clark, S.P., et al.,Biocomputing Informatics and Genome Projects, Smith, D.W., ed., Academic Press, New York, NY, pp. 28-31 (1993).
Cohen, B.I., and Cohen, F.E., “Chap. 7. Predictions of Protein Secondary and Tertiary Structure,” inBiocomputing Informatics and Genome Projects, Smith, D.W., ed., Academic Press, New York, NY, pp. 203-232 (1994).
Cunnigham, B.C., and Wells, J.A., “High-Resolution Epitope Mapping of hGH—Receptor Interactions by Alanine-Scanning Mutagenesis,”Science244:1081-1085, American Association for the Advancement of Science (1989).
Dayhoff, M.O., et al., “A Model of Evolutionary Change in Proteins,”Atlas Protein Sequence and Structure5:345-352, The National Biomedical Research Foundation (1979).
Devereux, J., et al., “A comprehensive set of sequence analysis programs for the VAX,”Nucl. Acid. Res. 12:387-395, IRL Press Limited, Oxford, England (1984).
Dölz, R., “Chap. 12. GCG: Analysis of Protein Sequences,” inMethods in Molecular Biology, vol. 24:Computer Analysis of Sequence Data, Part I, Griffin, A.M., and Griffin, H.G., eds., Humana Press Inc., Totowa, NJ, pp. 143-157 (1994).
Emilie, D., et al., “Administration of an Anti-Interleukin-6 Monoclonal Antibody to Patients with Acquired Immunodeficiency Syndrome and Lymphoma: Effect on Lymphoma Growth and on B Clinical Symptoms,”Blood84:2472-2479, The American Society for Hematology (1994).
Friguet, B., et al., “Measurements of the True Affinity Constant in Solution of Antigen-Antibody Complexes by Enzyme-Linked Immunosorbent Assay,”J. Immunol. Meth. 77:305-319, Elsevier Science Publishers B.V. (1985).
Foussat, A., et al., “Human interleukin-6 is in vivo an autocrine growth factor for human herpesvirus-8-infected maliganant B lymphocytes,”Eur. Cytokine Netw. 10:501-508, John Libbey Eurotext Ltd. (1999).
Haddad, E., et al., “Treatment of B-lymphoproliferative disorder with a monoclonal anti-interleukin-6 antibody in 12 patients: a multicenter phase 1-2 clinical trial,”Blood97:1590-1597, The American Society of Hematology (2001).
Henikoff, S., and Henikoff, J.G., “Amino acid substitution matrices from protein blocks,”Proc. Natl. Acad. Sci. USA89:10915-10919, National Academy of Sciences (1992).
Henikoff, S., “Chap. 4. Comparative Sequence Analysis: Finding Genes,” inBiocomputing Informatics and Genome Projects, Smith, D.W., ed., Academic Press, New York, NY, pp. 87-117 (1994).
Jakobovits, A., “Production of fully human antibodies by transgenic mice,”Curr. Opin. Biotech. 6:561-566, Current Biology Ltd. (1995).
Kabat, E.A. et al.,Sequences of proteins of immunological interest, 5th edition, U.S. Department of Health and Human Services, NIH publication 91-3242, pp. 1-22, 23-40, 103-148, 310-324, 647-709, 1138-1155, 1157-1171, 1229-1248, 1335-1343, 1571-1604, 2130-2154 (1991).
Lonberg, N., “Human antibodies from transgeneic animals,”Nat. Biotech. 23:1117-1125, Nature Publishing Group (Sep. 2005).
May, L.T., et al., “Anti-β-interferon antibodies inhibit the increased expression of HLA-B7 mRNA in tumor necrosis factor-treated human fibroblas

Affiliated with

Also associated with

Rating

Anti-IL-6 monoclonal antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Anti-IL-6 monoclonal antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-IL-6 monoclonal antibodies will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2693608